Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Funding will support the DC Cohort, the “largest citywide study of people living with HIV in the United States.”
The trial will enroll healthy volunteers to test the vaccine’s safety and ability to trigger an immune response.
Interim guidance from HIVMA and AIDSinfo covers lab visits, opioid treatment programs, pregnant women and more.
Researchers used a harmless virus to deliver a gene for a broadly neutralizing HIV antibody to cells, which produced the antibody over time.
Conducted in South Africa, it’s one of three major late-stage trials.
For the first time, researchers are assessing a pairing of a long-acting antiretroviral and a long-acting antibody.
Intravenous administration allowed the marginally effective BCG vaccination to work better in monkeys.
A long-term study found that kidney transplants between people with HIV have high success rates.
New forms of treatment and PrEP and, hopefully, an at least partially effective vaccine will be key to fighting the epidemic in the 2020s.
Calling all U.S. cisgender gay and bi men and trans and gender nonconforming people at risk for the virus.
“We’re very happy,” says PAC’s Murray Penner. But he’d like the federal agency to take these additional steps.
The money will help fund Birmingham’s efforts to achieve the UNAIDS 90-90-90 treatment goals.
Federal researchers describe two paths to a vaccine—and one of them uses high-tech computers to design a vaccine candidate!
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
A machine learning algorithm designed small sets of proteins that boasted the greatest potential to elicit a broad-based immune response.
Global research teams from three U.S. universities explore this HIV-tuberculosis link, thanks to a $6.2 million grant.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.